Brief: MEI Pharma, Kyowa Kirin Report Clinical Data On Zandelisib At European Hematology Association 2022 Hybrid Congress
10/06/2022 08:09
June 10 (Reuters) - Mei Pharma Inc MEIP.O :
* MEI PHARMA AND KYOWA KIRIN REPORT CLINICAL DATA ON
ZANDELISIB AT
EUROPEAN HEMATOLOGY ASSOCIATION 2022 HYBRID CONGRESS
* ZANDELISIB DEMONSTRATED 70.3% OBJECTIVE RESPONSE RATE AND
35.2%
COMPLETE RESPONSE RATE
* 9.9% OF PATIENTS DISCONTINUED THERAPY DUE TO A DRUG
RELATED
ADVERSE EVENT
Source text for Eikon: ID:nBw3gHhSba
Further company coverage: MEIP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia